tiprankstipranks
Advertisement
Advertisement
Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
PremiumRatingsAlumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
11d ago
Alumis price target lowered to $25 from $40 at H.C. Wainwright
Premium
The Fly
Alumis price target lowered to $25 from $40 at H.C. Wainwright
11d ago
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
Premium
The Fly
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
11d ago
Alumis price target raised to $33 from $22 at Morgan Stanley
PremiumThe FlyAlumis price target raised to $33 from $22 at Morgan Stanley
3M ago
Alumis price target raised to $32 from $18 at Guggenheim
Premium
The Fly
Alumis price target raised to $32 from $18 at Guggenheim
3M ago
Alumis announces $175M common stock offering
Premium
The Fly
Alumis announces $175M common stock offering
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100